Lynn Tetrault Biography and Net Worth

Director of Rhythm Pharmaceuticals

Ms. Tetrault has served as a member of our Board since December 2020. She is a global business leader with more than 25 years of experience in the health care industry. Ms. Tetrault spent most of her career with Astra Zeneca PLC, serving in a variety of senior roles, including as EVP of Human Resources and Corporate Affairs for seven years. She joined the Board of Neo Genomics Clinical Laboratories in 2015 and is currently Lead Independent Director. Ms. Tetrault is the founder of Anahata Leadership, an advisory firm focused on supporting the leadership and development of executive women. She is a Fellow of Simmons University’s Institute for Inclusive Leadership and is a Director of Paradigm for Parity, a non-profit organization whose mission is to close the gender parity gap in corporate leadership by 2030. She began her career as a lawyer in private healthcare practice in Boston. Ms. Tetrault holds a B.A. from Princeton University and a J.D. from the University of Virginia.

What is Lynn A. Tetrault's net worth?: The estimated net worth of Lynn A. Tetrault is at least $147,060.00 as of September 10th, 2024. Ms. Tetrault owns 3,000 shares of Rhythm Pharmaceuticals stock worth more than $147,060 as of October 24th. This net worth approximation does not reflect any other assets that Ms. Tetrault may own. Learn More about Lynn A. Tetrault's net worth.
How do I contact Lynn A. Tetrault?: The corporate mailing address for Ms. Tetrault and other Rhythm Pharmaceuticals executives is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. Rhythm Pharmaceuticals can also be reached via phone at (857) 264-4280 and via email at [email protected]. Learn More on Lynn A. Tetrault's contact information.
Has Lynn A. Tetrault been buying or selling shares of Rhythm Pharmaceuticals?: Lynn A. Tetrault has not been actively trading shares of Rhythm Pharmaceuticals within the last three months. Most recently, Lynn A. Tetrault sold 17,501 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $49.65, for a transaction totalling $868,924.65. Following the completion of the sale, the director now directly owns 3,000 shares of the company's stock, valued at $148,950. Learn More on Lynn A. Tetrault's trading history.
Who are Rhythm Pharmaceuticals' active insiders?: Rhythm Pharmaceuticals' insider roster includes Pamela Cramer (Insider), Jennifer Good (Director), Jennifer Lee (EVP), Yann Mazabraud (EVP), David Meeker (CEO), Joseph Shulman (Insider), Hunter Smith (CFO), and Lynn Tetrault (Director). Learn More on Rhythm Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Rhythm Pharmaceuticals?: In the last twelve months, insiders at the sold shares 25 times. They sold a total of 331,893 shares worth more than $15,042,769.51. The most recent insider tranaction occured on September, 17th when Director Jennifer L Good sold 31,751 shares worth more than $1,663,752.40. Insiders at Rhythm Pharmaceuticals own 5.6% of the company. Learn More about insider trades at Rhythm Pharmaceuticals.
Information on this page was last updated on 9/17/2024.

Lynn A. Tetrault Insider Trading History at Rhythm Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/10/2024	Sell	17,501	$49.65	$868,924.65	3,000
8/26/2024	Sell	4,300	$50.01	$215,043.00	3,000

Lynn A. Tetrault Buying and Selling Activity at Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Company Overview

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $49.02

$48.17

$49.63

50 Day Range

MA: $49.24

$44.19

$54.55

2 Week Range

Now: $49.02

$21.34

$55.64

Volume

387,359 shs

Average Volume

533,367 shs

Market Capitalization

$3.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.